Search results
Added:
1 year ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more
Added:
8 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Added:
1 year ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further…
View more
Sex Difference in Relative Survival Following PCI
Added:
1 year ago
Original Research
Added:
1 year ago
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD).The FLOW trial (NCT03819153) is designed to assess the effect of…
View more
Oxidative Stress Genes Predict Survival in STEMI
Added:
1 year ago
Original Research
Added:
1 year ago
Added:
2 months ago
Source:
Interventional Cardiology Review Journal
Long-term follow-up from the FAMOUS-NSTEMI trial suggests that a fractional flow reserve-guided strategy for managing patients with non-ST-segment elevation myocardial infarction (NSTEMI) does not reduce adverse cardiovascular outcomes compared to standard angiography-guided care.¹MethodologyFAMOUS-NSTEMI was a prospective, randomised, controlled trial that enrolled 350 patients with NSTEMI…
View more
Added:
1 year ago
EuroPCR 25 - Substudy findings from ILUMIEN-IV show that virtual flow reserve was slightly higher after angiography guidance rather than an optical coherence tomography (OCT)-based physiology assessment after percutaneous coronary intervention (PCI) in high-risk angiographic lesions.We are joined by Dr Thomas Johnson (Bristol Heart Institute, Bristol, UK) to discuss findings from a retrospective…
View more
The Coronary Microcirculation Re-explored
Added:
7 months ago
Review Article